Cenexi: OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE's Multi-Target Second-Generation COVID-19 Vaccine
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629005918/en/ OSE Immunotherapeutics (Paris:OSE)(ISIN: FR0012127173...
Read full article »
Cenexi is a France-based CDMO that provides services such as dosage forms and medicine formulation development for the healthcare sector.
Read more